key: cord-0744909-3pusic54
authors: Cortinovis, Monica; Perico, Norberto; Remuzzi, Giuseppe
title: Long-term follow-up of recovered patients with COVID-19
date: 2021-01-08
journal: Lancet
DOI: 10.1016/s0140-6736(21)00039-8
sha: 14b6c0bf961306eb6e69c6ba8d32ce6656994f7d
doc_id: 744909
cord_uid: 3pusic54

nan

By early January, 2021, COVID19, caused by the severe acute respiratory syndrome coronavirus 2 (SARSCoV2), had resulted in more than 83 million confirmed cases and more than 1·8 million deaths. The clinical spectrum of SARSCoV2 infection is wide, encompassing asymp tomatic infec tion, fever, fatigue, myalgias, mild upper respiratory tract illness, severe lifethreatening viral pneumonia requiring admission to hospital, and death. 1 Physicians are observing persisting symptoms and unexpected, substantial organ dysfunction after SARSCoV2 infection in an increasing number of patients who have recovered, as previously observed in the SARS outbreak. 2 However, COVID19 is a new disease and uncertainty remains regarding the

colleagues must be congratulated for developing a comprehensive and well designed score for integrating thrombotic and bleeding risks in patients with ACS. Compared with previous scoring approaches (appendix), the PRAISE score is based on one of the largest study populations and shows superior performance when externally validated. The variables included in the score are easily accessible from patient discharge information. Therefore, the score is simple, intuitive, and easy to implement in everyday clinical practice, also thanks to the PRAISE score calculator available online. Of note, previous scores have often been derived from cohorts of patients admitted for both stable coronary artery disease and ACS. [4] [5] [6] As these two clinical entities are likely to be associated with different risk profiles, the training and validation of the PRAISE score on cohorts of only patients with ACS should be considered as an additional strength. Although the ability of machine learning based models to overcome limitations of traditional regressionbased risk prediction systems remains a subject of debate, D'Ascenzo and colleagues' study 7 does not allow conclusions to be drawn in this regard, since a comparison with conventional statistical models is lacking. [8] [9] [10] [11] The study of D'Ascenzo and colleagues surely represents a considerable step forwards in enhancing the risk stratification of patients with ACS. Nevertheless, some caution must be applied when analysing the results. There might be confounding by indication due to the observational design of the derivation cohorts. Also, the prediction of events based on clinical features (eg, age, haemoglobin concentration, eGFR, and LVEF) that correlate with both outcomes (ie, ischaemia and bleeding events) might mean that the model does not always lead to therapeutic decisions that ultimately improve prognosis. Whereas the PRAISE models were For the PRAISE score online calculator see https://praise. hpc4ai.it derived on a heterogeneous cohort including patients from five continents, validation was done on patients mainly enrolled from Italian centres. Therefore, further validation on additional cohorts remains desirable. Finally, the effectiveness of the PRAISE score in improving patient outcomes should be prospectively tested in randomised controlled trials.

We declare no competing interests. possible longterm health sequelae. This is particularly relevant for patients with severe symptoms, including those who required mechanical ventilation during their hospital stay, for whom longterm com plications and incomplete recovery after discharge would be expected. Unfortunately, few reports exist on the clinical picture of the aftermath of COVID19.

The study by Chaolin Huang and colleagues 3 in The Lancet is relevant and timely. They describe the clinical followup of a cohort of 1733 adult patients (48% women, 52% men; median age 57·0 years, IQR 47·0-65·0) with COVID19 who were discharged from Jin Yintan Hospital (Wuhan, China). 6 months after illness onset, 76% (1265 of 1655) of the patients reported at least one symptom that persisted, with fatigue or muscle weakness being the most frequently reported symptom (63%, 1038 of 1655). More than 50% of patients presented with residual chest imaging abnormalities. Disease severity during the acute phase was independently associated with the extent of lung diffusion impairment at followup (odds ratio 4·60, 95% CI 1·85-11·48), with 56% (48 of 86) of patients requiring highflow nasal cannula, noninvasive ventila tion, and invasive mechanical ventilation during their hospital stay having impaired pulmonary diffusion capacity. 3 These findings are consistent with those from earlier small studies that reported lingering radiological and pulmonary diffusion abnormalities in a sizeable proportion of COVID19 patients up to 3 months after hospital discharge. 4, 5 Evidence from previous coronavirus out breaks suggests that some degree of lung damage could persist, as shown in patients who recovered from SARS, 38% of whom had reduced lung diffusion capacity 15 years after infection. 2 Although SARSCoV2 primarily affects the lungs, several other organs, including the kidney, can also be affected. 6 Therefore, Huang and colleagues assessed the sequelae of extrapulmonary manifestations of COVID19. Unexpectedly, 13% (107 of 822) of the patients who did not develop acute kidney injury during their hospital stay and presented with normal renal function, based on estimated glomerular filtration rate (eGFR) during the acute phase, exhibited a decline in eGFR (<90 mL/min per 1·73 m²) at follow up. 3 However, this finding must be interpreted with caution. Because repeated GFR measurement using a goldstandard technique-such as plasma clearance of iohexol or iothalamate-would presumably have been unfeasible in such a large cohort of patients, GFRestimating equations, such as that used in the present study, do not enable a sound assessment of renal function, which can be overestimated or underestimated compared with measured GFR. 7 Importantly, deep venous thrombosis was not diagnosed in any of the patients who underwent ultrasonography at followup. 3 This is an encouraging finding, in light of the frequent development of venous thromboembolism in patients with COVID19 who are critically ill while in hospital. 6 Even though the study offers a comprehensive clinical picture of the aftermath of COVID19 in patients who have been admitted to hospital, only 4% (76 of 1733) were admitted to an intensive care unit (ICU), 3 rendering the information about the longterm consequences in this particular cohort inconclusive. However, previous research on patient outcomes after ICU stays suggests that several patients with COVID19 who were critically ill during their hospital stay will subsequently face impairments regarding their cognitive and mental health or physical function far beyond their hospital discharge. 8 Outpatient clinics that are dedicated to following up on lasting disabilities in the large number of patients who previously had COVID19 are opening in many hospitals, especially in areas where large SARSCoV2 outbreaks have occurred. However, this initiative implies a further burden on the healthcare Barcroft Media/Getty Images In The Lancet, David Steindl and colleagues describe the case of a 44yearold man who was poisoned by a novichok organophosphorus nerve agent. 1 The man was a passenger on a domestic flight in Russia when he became confused, and vomited and collapsed unconscious; 2 h later, he was hospitalised in Omsk, Russia, and treated for respiratory failure and coma. After transfer by air ambulance to Berlin, Germany, features of the cholinergic toxidrome (ie, small or pinpoint pupils, bradycardia, sweating, and hypersalivation) allowed a diagnosis of organophos phorus poisoning to be made. Assessments done by a doctor from the air ambulance crew before transfer to Germany did not indicate that organophosphorus poisoning had yet been diagnosed or antidotes used. However, atropine was later detected in urine. With administration of antidotes and intensive care at CharitéUniversitätsmedizin Berlin, the man made a full recovery.

Organophosphorus compounds inhibit acetylcho linesterase at cholinergic synapses in the CNS, autonomic nervous system, and neuromuscular junctions, causing accumulation of acetylcholine and overstimulation of cholinergic receptors (acute cholinergic crisis). 2 A diag nosis was made in Germany based on clinical features and severely inhibited cholinesterase activity and was later confirmed by detection of novichok compounds in blood samples (data not in the public domain). This case is exceptionally well documented, showing typical cholinesterase inhibition, neuromuscular dysfunction, and antidote administration.

This case report draws parallels with incidents from 2018 of novichok poisoning in Salisbury and Amesbury in the UK. 3, 4 In Salisbury, a woman and man were found unresponsive in a public place; initially thought to have taken opioids, they were stabilised at the scene by paramedics and taken to hospital. A policeman also became ill; all affected individuals Organophosphorus poisoning: the wet opioid toxidrome system in terms of human and economic resources, in addition to conventional healthcare services. Unfortunately, these clinics are largely unaffordable in most lowincome or middleincome countries that have also been severely affected by the COVID19 pandemic. However, the success of this approach to monitoring and treating patients with COVID19 who have recovered creates an opportunity to concomitantly conduct integrated multidisciplinary research studies during 1-2 years of followup, as is currently happening in the UK and USA. 9 These studies will improve our understanding of the natural history of COVID19 sequelae and the factors or mediators involved, and enable us to assess the efficacy of therapeutic interventions to mitigate the longterm consequences of COVID19 on multiple organs and tissues. This is consistent with the syndemic nature of the COVID19 pandemic, 10 and has implications for the longterm followup of COVID19 sequelae, which in most instances should be interpreted against a background of an array of noncommunicable diseases and social and income inequalities that exacerbate the adverse effects of each of these diseases in many communities.

Janssen Pharmaceutical, Akebia Therapeutics, Alnylam, Boehringer Ingelheim, Inception Sciences Canada, Omeros, and Catalyst Biosciences, all outside of the submitted work

Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS

Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study

Longterm bone and lung consequences associated with hospitalacquired severe acute respiratory syndrome: a 15year followup from a prospective cohort study

6month consequences of COVID19 in patients discharged from hospital: a cohort study

Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Followup study of the pulmonary function and related physiological characteristics of COVID19 survivors three months after recovery

Immunity, endothelial injury and complementinduced coagulopathy in COVID19

Estimated GFR: time for a critical appraisal

Cooccurrence of postintensive care syndrome problems among 406 survivors of critical illness

The lasting misery of coronavirus longhaulers

Offline: COVID19 is not a pandemic